ReviewJournal of translational medicine2026
Decoding mitochondrial signaling: neutrophil-tumor cell crosstalk in orchestrating cancer progression.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondria regulate energy metabolism, redox balance, cell survival, and innate immune signaling. Neutrophils, the most abundant circulating innate immune effector cells, play an essential role in reshaping the tumor microenvironment and can exhibit both anti-tumor and tumor-supporting behaviors. Although mitochondrial processes are increasingly recognized as key drivers of neutrophil functional diversity and neutrophil-tumor cell communication, a systematic synthesis centered on mitochondria remains limited. MAIN BODY: The review opens with an overview of defining features of mitochondrial biology, including fission and fusion dynamics, oxidative stress responses, calcium balance, apoptosis-related pathways, and mitochondrial damage signals that influence immune activation. Mitochondria-dependent programs supporting neutrophil survival, lifespan control, and physiological defense functions are then outlined to show how subcellular metabolism shapes innate effector activity. The focus subsequently shifts to mitochondrial contributions in tumor-supportive interactions between neutrophils and tumor cells, highlighting the capacity of mitochondrial signals from both sides to reinforce tumor-promoting neutrophil traits, tumor cell aggressiveness, and bidirectional crosstalk. Emerging strategies capable of redirecting neutrophil mitochondria toward anti-tumor phenotypes are finally summarized, including stimulation of mitochondrial biogenesis, delivery of mitochondrial-targeted proteins to enhance neutrophil-driven immunity, dual disruption of extracellular traps and tumor mitochondria to break tumor-supportive feedback, and modulation of mitochondrial quality-control and oxidative signaling to rebalance tumor-supportive neutrophils.
conclusionA mitochondria-centered subcellular perspective provides a more cohesive framework for understanding neutrophil-tumor communication and may help inform the development of subcellularly targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.